KPLKwality Pharmaceuticals Ltd.
Kwality Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹29.03 Crore on Total Income of ₹182 Crore
- Earnings
- Pharmaceuticals

Kwality Pharmaceuticals (NSE: KPL) reported consolidated total income of ₹181.99 crore and net profit of ₹29.03 crore for the quarter ended 30 Sep 2026. On a standalone basis, total income was ₹181.94 crore and net profit ₹29.02 crore. The company said so in a filing on 12 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹181.99 crore, up 62.6% YoY and 11.7% QoQ
- Net profit and EPS: ₹29.03 crore, up 105.6% YoY; basic EPS ₹27.93
- Finance costs: ₹2.99 crore, up 5.4% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹181.94 crore, up 62.1% YoY and 11.6% QoQ
- Net profit and EPS: ₹29.02 crore, up 105.6% YoY; basic EPS ₹27.97
- Finance costs: ₹2.99 crore, up 5.4% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 181.99 | 111.95 | +62.6% | 162.97 | +11.7% | |
| Revenue from operations | 181.22 | 111.05 | +63.2% | 162.35 | +11.6% |
| Other income | 0.77 | 0.90 | -14.1% | 0.62 | +23.8% |
| 29.03 | 14.12 | +105.6% | 25.62 | +13.3% | |
| Profit before tax | 42.22 | 18.45 | +128.8% | 33.99 | +24.2% |
| Finance costs | 2.99 | 2.84 | +5.4% | 2.66 | +12.6% |
| Depreciation | 5.36 | 4.96 | +8.1% | 4.99 | +7.3% |
| Net profit margin | 15.95% | 12.61% | +3.34 pp | 15.72% | +0.23 pp |
| EPS, basic (₹) | 27.93 | 13.60 | +105.4% | 24.69 | +13.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Profit grew faster than income in the quarter. Revenue from operations rose 63.2% to ₹181.22 crore and total income rose 62.6% to ₹181.99 crore, while net profit rose 105.6% to ₹29.03 crore and profit before tax rose 128.8% to ₹42.22 crore.
Other income was ₹0.77 crore, down 14.1% from ₹0.90 crore a year earlier, and is 0.4% of total income and 1.8% of profit before tax. Finance costs of ₹2.99 crore are 1.6% of total income, and depreciation rose 8.1% to ₹5.36 crore. The statement shows no exceptional items for the quarter; the year ended 31 Mar 2026 shows one of ₹82.94 lakh.
The company says its EBITDA margin was 27.5% against 23.4% in the same quarter last year, and its PAT margin 16% against 13%. It attributes the margin expansion to improved operating leverage and a favourable product mix.
In the half year, the company says debtor days were 178 against 203 in FY26, inventory days 77 against 111, and payable days 126 against 144. It says the cash conversion cycle fell to 130 days from 170 days in FY26 and 297 days in FY23.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 181.94 | 112.21 | +62.1% | 162.97 | +11.6% | |
| Revenue from operations | 181.17 | 111.31 | +62.8% | 162.35 | +11.6% |
| Other income | 0.77 | 0.90 | -14.1% | 0.62 | +23.8% |
| 29.02 | 14.12 | +105.6% | 25.63 | +13.3% | |
| Profit before tax | 42.22 | 18.45 | +128.8% | 33.99 | +24.2% |
| Finance costs | 2.99 | 2.84 | +5.4% | 2.66 | +12.6% |
| Depreciation | 5.36 | 4.96 | +8.1% | 4.99 | +7.3% |
| Net profit margin | 15.95% | 12.58% | +3.37 pp | 15.72% | +0.23 pp |
| EPS, basic (₹) | 27.97 | 13.60 | +105.7% | 24.70 | +13.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone profit also grew faster than income. Total income rose 62.1% to ₹181.94 crore, while net profit rose 105.6% to ₹29.02 crore and profit before tax rose 128.8% to ₹42.22 crore.
Standalone revenue from operations was ₹181.17 crore against ₹111.31 crore a year earlier, up 62.8%. Other income was ₹0.77 crore against ₹0.90 crore, and is 1.8% of profit before tax of ₹42.22 crore. Finance costs are 1.6% of total income.
Basic EPS was ₹27.97 against ₹13.60 a year earlier, up 105.7%. The standalone net profit margin was 15.95% against 12.58% in the same quarter last year.
Inference
The company says M/s. Vijay Mehra & Co., Chartered Accountants, resigned as statutory auditors with effect from 12 Nov 2026, and states the reason as pre-occupation in other assignments. The resignation letter states that the firm raised no concerns with the management of the Company and that there are no material reasons for the resignation other than those stated. Before resigning, the firm issued a limited review report dated 12 Nov 2026 on the quarter's results.
B S R & Co. LLP (Firm Registration No. 101248W/W-100022) was appointed to fill the casual vacancy with effect from 12 Nov 2026, subject to approval by members at a general meeting to be convened within three months. The filing says the firm will hold office until the conclusion of the 44th Annual General Meeting.
The company says it acquired 4 acres adjacent to its Amritsar manufacturing campus for Unit 7, a planned facility with 4+ injectable lines and 6+ oral solid dosage lines, and expects the oncology manufacturing expansion to be completed by June 2027. It also says it received EU-GMP certification from Hungary for its Cephalosporin and Oncology facilities, and has completed bioequivalence studies for 19 of the 40 molecules in its programme for global filings.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Get the Blacklitt app
Hold Kwality Pharmaceuticals Ltd.? See it with the rest of your portfolio
Bring in your stocks and mutual funds once. Blacklitt sets them against a plan for your goals and risk, and tells you what to change and why.
Fee-only SEBI Registered Investment Adviser, INA000022428. No commission from any fund house, broker or company.
Scan with your phone camera to get the app.
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

